Fusion Antibodies plc (AIM: FAB ) has confirmed COVID-19 has had little impact on trading and full year results remain in line with expectations outlined in the Company's trading update on 29 January 2020.
The Company remains fully operational and is conducting vital business for its customers including many leading developers of therapeutic drugs and diagnostics working on solutions relating to COVID-19. The Company has been engaged and continues to receive further expressions of interest regarding its services for a number of projects in this therapeutic area.
The Company expects to provide a more detailed trading update in April post the financial year end.
Shares are trading up 20%.
Paul Kerr, Fusion's Chief Executive Officer, said: "At the current time, the pharmaceutical industry has a vital role to play in overcoming the Covid-19 pandemic and Fusion's clients are heavily involved in this work. We are well placed to support our clients in this vital work and believe that our services and products can help accelerate the finding of the solution."